SHUR IQ · Rugiet / Rugiet — Due Diligence · Shur Creative Partners Diligence Read June 3, 2026 Interactive View →
RUGIET-V02-2026-06 // DILIGENCE SUITE

ShurIQ Diligence Suite

Five views for a follow-on decision on a small direct-to-consumer telehealth brand in men's sexual health. We place Rugiet against the platforms that own customer acquisition, rank it across the broad market and the focused-challenger set, set out the eight checkable diligence flags by severity, and bring the revenue gap, the senior loan, and the verify list onto one screen. Every Rugiet figure carries its company-asserted qualifier; the compounded, not-FDA-approved status of the core product is verified.

5
VIEWPORTS
8
DILIGENCE FLAGS
40
MACRO SCORE
31
SENIOR LOAN $M
4
REVENUE GAP ×
VIEWPORT 01
Market Position
We place the field by the two powers that decide this market — control of how a customer is acquired, and the capital and scale that fund it. Hims and Ro sit high on both; Rugiet sits low on both, a single-vertical brand buying traffic in the same auction as multi-billion-dollar platforms.
BRANDS 7 AXES ACQUISITION × CAPITAL
LAUNCH VIEWPORT
VIEWPORT 02
Macro Rank
Seven players ranked across the full men's sexual-health market on a 0–100 structural-advantage scale, acquisition control weighted heaviest. Hims leads at 91 on roughly $2.35B; Rugiet lands at 40, last, on stage, channel scale, and regulatory exposure, not on the formulation.
TOP 91 HIMS & HERS RUGIET 40 / 100 TIERS 5
LAUNCH VIEWPORT
VIEWPORT 03 · THE CENTERPIECE
The Diligence Flags
The eight material, specific, checkable issues a follow-on has to price, set out by severity. Each flag carries its one-line finding, why it changes the decision, and what to verify next — from the unapproved headline molecule and the $100M-versus-$10–25M revenue gap to the $31M senior loan and the auto-renewal exposure.
FLAGS 8 HIGH 5 MEDIUM 3
LAUNCH VIEWPORT
VIEWPORT 04
Micro Rank
Among the focused ED challengers the formulation earns a higher floor, then stops. The 3-in-1 compounded dissolvable tablet is the most novel product in the set, which lifts Rugiet to 46, above its macro standing and ahead of the unbranded long tail — held back by undisclosed scale and the deepest compounded-drug exposure.
TOP 90 HIMS SH RUGIET 46 / 100 CHALLENGERS 6
LAUNCH VIEWPORT
VIEWPORT 05
Composite Dashboard
One screen. Rugiet's five-dimension profile, the revenue triangulation (>$100M company-asserted against a $10–25M tracker band and our $15–40M read), the $31M senior loan callout, and the verify list that closes the gap between the headline and what diligence can confirm.
SCORE 40 PROFILE 5-DIM VERIFY 7
LAUNCH VIEWPORT